ClinicalTrials.gg

Program

HRS5580

A development code. Also written as “HRS5580 for injection combined with palonosetron hydrochloride;” and “HRS5580 for injection combined with palonosetron hydrochloride”.

In Jiangsu HengRui Medicine's pipeline, NK1. Its studies are mostly in Vomiting · Postoperative Nausea and Vomiting, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Jun 13, 20242 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine21 open or runningphase 2since Jun 13, 2024Jun 13, 2024Dec 2026phase 2 · NCT07709897
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS5580, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 13, 2024First study: phase 2 study in Preventing of Postoperative Nausea and Vomiting in AdultsFirst studyNCT06475846 · 235 enrolled · China
  2. Jul 8, 2026Phase 2 study in VomitingNCT07709897 · 260 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in VomitingNCT07709897

TargetBeta

“NK1”the company's pipeline, read by Claude · source

Other programs on TACR1

ProgramCompanyFurthest phaseStudies
AprepitantruleMerckphase 427
elinzanetantruleBayerphase 324
tradipitantruleVanda Pharmaceuticalsphase 319
fosnetupitantruleHelsinn Healthcarephase 32

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07709897Vomiting · China2RecruitingDec 2026260
NCT06475846Preventing of Postoperative Nausea and Vomiting in Adults · China2CompletedOct 29, 2024235

How it is read

Names in the registry

  • “HRS5580”, 3 entries
  • “HRS5580 for injection combined with palonosetron hydrochloride;”, 1 entry
  • “HRS5580 for injection combined with palonosetron hydrochloride”, 1 entry

Codes read as this program: HRS5580.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.